Heterozygous TREM2 Mutation in Semantic Variant of Primary Progressive Aphasia

Min-Jin Ji, Sungwon Jung, Ha-Eun Seo, Sang-Young Kim, Woo-Ram Kim, Sora Kim, Jin Sook Lee, Young Noh, Hyun Young Jin, Sungwon Jung, Min-Jin Ji

Department of Health Science and Technology, GAIST, Gachon University, Incheon, Korea
Department of Genome Medicine and Science, Gachon University College of Medicine, Incheon, Korea
Gachon Institute of Genome Medicine and Science, Gachon University Gil Medical Center, Incheon, Korea
Neuroscience Research Institute, Gachon University, Incheon, Korea
Neurology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea

Dear Editor,

Triggering receptor expressed on myeloid cells 2 (TREM2) protein, which is expressed on the membranes of a subset of myeloid cells, regulates immune responses in the brain. Genetic variants of TREM2 are associated with increased risks of developing Alzheimer’s disease (AD) and frontotemporal dementia (FTD). In this study we identified a semantic variant in a primary progressive aphasia (svPPA) patient with one heterozygous TREM2 mutation.

The 50-year-old right-handed male presented with a 10-year history of progressive anomia and comprehension difficulty. He also exhibited irritable and aggressive behaviors as well as alcohol and gambling addictions. Neuropsychological testing revealed poor performance in most tasks, but his visuospatial function was relatively spared (84.37th percentile). His language function assessed using the Western Aphasia Battery was indicative of Wernicke’s aphasia. As shown in Fig. 1A, which was adapted from our previous report, MRI revealed atrophy in the bilateral anterior temporal lobes (left > right), while [18F]THK5351 positron emission tomography (PET) revealed greater [18F]THK5351 retention in the anteroinferior temporal regions. [18F]FDG PET showed hypometabolism in the bilateral anterior temporal areas (left > right) (Supplementary Material, Supplementary Fig. 1 in the online-only Data Supplement).

Whole-exome sequencing identified one heterozygous TREM2 variant in the proband: c.574G>A, p.Ala192Thr (NM_018965). Sanger sequencing for the proband (II-4) and additional unaffected family members (I-3, II-2, and II-3) confirmed that the variant segregated with the phenotype in the family. Moreover, there was neither any gene mutation associated with FTD (e.g., TARDP, MAPT, GRN, C9orf72, VCP, CHMP2B, FUS, ITM2B, TBK1, and TBP) nor any gene mutation that is not commonly linked to FTD (e.g., PSEN1).

The heterozygous rare variants of TREM2 including R47H, D87N, and Q33X reportedly associated with FTD (e.g., TARDP, MAPT, GRN, C9orf72, VCP, CHMP2B, FUS, ITM2B, TBK1, and TBP) or any gene mutation that is not commonly linked to FTD (e.g., PSEN1).

This study was subject to some limitations. First, since the patient did not undergo amyloid PET, and so we could not exclude the possibility of amyloid pathology being present. However, the [18F]FDG PET findings indicated that the possibility of AD would be low, even if it were. Second, we presumed that the proband had a family history of this neurological disease because his father and half-brother had similar clinical phenotypes. However, we could
not confirm that the mutation in TREM2 was inherited, since it was not possible to obtain any clinical diagnosis, neuroimaging, or genetic test results from any of them.

To our knowledge, this is the first report of an svPPA patient with the rare TREM2 heterozygous A192T variant. Although rare cases of the genetic transmission of svPPA have been reported, our findings suggest that the A192T variant is associated with an increased risk of svPPA. Associations of TREM2 variants with the risk of early- or late-onset AD as well as FTD may be due to immunological and inflammatory dysregulation in the central nervous system.

Supplementary Materials
The online-only Data Supplement is available with this article at https://doi.org/10.3988/jcn.2020.16.2.352.

Author Contributions
Conceptualization: Young Noh, Jin Sook Lee. Data curation: Sungwon Jung, Sora Kim. Formal analysis: Jin Sook Lee, Woo-Ram Kim. Funding acquisition: Young Noh. Investigation: Young Noh. Supervision: Young Noh, Jin Sook Lee. Validation: Sungwon Jung, Ha-Eun Seo, Sang-Young Kim. Writing-original draft: Min-Jin Ji. Writing-review & editing: all authors.

Fig. 1. Brain images, family pedigree, and sanger sequencing. A: Axial and coronal [18F]THK5351 positron emission tomography and T1-weighted magnetization-prepared rapid gradient-echo brain MRI images of an semantic variant in a primary progressive aphasia patient. [18F]THK5351 retention was increased in the bilateral anteroinferior temporal areas (left>right). B: Family pedigree. Arrow indicates the proband with the A192T variant (black filled square). A slash through a symbol indicates a deceased family member. White symbols represent unaffected family members, and white symbols with a center black dot represent presumed affected individuals carrying the TREM2 variant. A question mark indicates an unknown family history. The dashed line indicates an unmarried relationship. C: Sanger sequencing of TREM2 in the proband (II-4) and unaffected family members (II-3, II-2, and II-3). SUV: standardized uptake value.

ORCID iDs
Min-Jin Ji https://orcid.org/0000-0002-2067-2184
Sungwon Jung https://orcid.org/0000-0001-6002-554X
Ha-Eun Seo https://orcid.org/0000-0003-4452-0908
Sang-Young Kim https://orcid.org/0000-0002-2620-3071
Woo-Ram Kim https://orcid.org/0000-0003-1361-4426
Sora Kim https://orcid.org/0000-0002-9424-6786
Jin Sook Lee https://orcid.org/0000-0002-3652-3570
Young Noh https://orcid.org/0000-0002-9633-3314

Conflicts of Interest
The authors have no potential conflicts of interest to disclose.

Acknowledgements
This study was supported by a grant from the Korea Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare of the Republic of Korea (grant No: HI14C1135) and by the Brain Research Program of the National Research Foundation of Korea (NRF) Grant funded by the Korean Government (MSIT) (no. 2018M3C7A1056889).

REFERENCES
1. Forabosco P, Ramasamy A, Trabzuni D, Walker R, Smith C, Bras J, et al. Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol Aging 2013;34:2699-2714.
2. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013;368:117–127.
3. Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, et al. Heterozygous \textit{TREM2} mutations in frontotemporal dementia. \textit{Neurobiol Aging} 2014;35:934.e7-934.e10.

4. Lee H, Seo S, Lee SY, Jang JJ, Woo SH, Lee KM, et al. \[18F\]-THK5351 PET imaging in patients with semantic variant primary progressive aphasia. \textit{Alzheimer Dis Assoc Disord} 2018;32:62-69.

5. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. \textit{Neurology} 2011;76:1006-1014.

6. Bonham IW, Sirkis DW, Fan J, Aparicio RE, Tse M, Ramos EM, et al. Identification of a rare coding variant in \textit{TREM2} in a Chinese individual with Alzheimer's disease. \textit{Neurocase} 2017;23:65-69.

7. Park JE, Kim HJ, Kim YE, Jang H, Cho SH, Kim SJ, et al. Analysis of dementia-related gene variants in APOE \(\varepsilon4\) noncarrying Korean patients with early-onset Alzheimer's disease. \textit{Neurobiol Aging} 2020;85:155.e5-155.e8.

8. Hodges JR, Mitchell J, Dawson K, Spillantini MG, Xuereb JH, McMonagle P, et al. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. \textit{Brain} 2010;133:300-306.

9. Carmona S, Zahs K, Wu E, Dakin K, Bras J, Guerreiro R. The role of \textit{TREM2} in Alzheimer's disease and other neurodegenerative disorders. \textit{Lancet Neurol} 2018;17:721-730.